Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Genentech researchers uncover epigenetic regulator of pancreatic cancer cells

Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin.

11 Dec 2017

Clinical trial shows promising results for treatment of patients with recurrent high-grade glioma

New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.

28 Oct 2017

New topical treatment to combat skin cancer yields promising results in preliminary study

Researchers at the University of São Paulo (USP), in Brazil, are testing a technique in mice that combines low-intensity electric current with a formulation containing nanoencapsulated chemotherapy to treat skin cancer.

6 Oct 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.

17 Apr 2017

Combination therapy holds great promise to clear precancerous skin lesions

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patients participating in a clinical trial.

19 Dec 2016

Study shows new drug combination effective in treating precancerous skin lesions

A combination of two topical drugs that have been in use for years triggers a robust immune response against precancerous skin lesions, according to a new study. The research, from Washington University School of Medicine in St. Louis and Harvard Medical School, shows that the therapy activates the immune system's T cells, which then attack the abnormal skin cells.

21 Nov 2016

Clinical study finds two topical skin creams as effective noninvasive treatments for low-risk superficial BCC

Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions.

3 Jun 2016

Retroviral replicating vector can extend lives of brain cancer patients

Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with the disease.

2 Jun 2016

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

St. Jude Children's Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients.

10 May 2016

Researchers develop metastasis-on-a-chip system to advance cancer investigation, drug discovery

Advances in personalized medicine allow doctors to select the most promising drugs for certain types of malignant tumors.

24 Mar 2016

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.

22 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

NUS-led study discovers potential therapeutic approach against colorectal cancer

A study led by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.

11 Jan 2016

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.

23 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.